pravastatin

Summary

Summary: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).

Top Publications

  1. ncbi Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
    James Shepherd
    University Department of Pathological Biochemistry, University of Glasgow, Royal Infirmary, Scotland, Glasgow, UK
    Lancet 360:1623-30. 2002
  2. ncbi Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study
    D J Freeman
    Department of Biological Sciences, University of Durham, Durham, UK
    Circulation 103:357-62. 2001
  3. ncbi Long-term follow-up of the West of Scotland Coronary Prevention Study
    Ian Ford
    Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom
    N Engl J Med 357:1477-86. 2007
  4. ncbi Differential metabolic effects of distinct statins
    Kwang Kon Koh
    Vascular Medicine and Atherosclerosis Unit, Cardiology, Gachon University, Gil Medical Center, 1198 Kuwol dong, Namdong gu, Incheon 405 760, Republic of Korea
    Atherosclerosis 215:1-8. 2011
  5. ncbi Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial
    Haruo Nakamura
    Mitsukoshi Health and Welfare Foundation, Tokyo, Japan
    Lancet 368:1155-63. 2006
  6. ncbi Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial
    Ming Yuan Tseng
    Department of Neurosurgery, Addenbrooke s Hospital, University of Cambridge, Cambridge CB2 2QQ, United Kingdom
    Stroke 36:1627-32. 2005
  7. pmc Genome-wide association of lipid-lowering response to statins in combined study populations
    Mathew J Barber
    Department of Human Genetics, University of Chicago, Chicago, Illinois, United States of America
    PLoS ONE 5:e9763. 2010
  8. ncbi Pravastatin limits radiation-induced vascular dysfunction in the skin
    Valerie Holler
    Institute for Radiological Protection and Nuclear Safety IRSN, DRPH, SRBE, Laboratory of Radiopathology, Fontenay aux Roses, France
    J Invest Dermatol 129:1280-91. 2009
  9. pmc Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels
    N P Tatonetti
    Biomedical Informatics Training Program, Stanford University, Stanford, California, USA
    Clin Pharmacol Ther 90:133-42. 2011
  10. ncbi Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project
    Marc A Pfeffer
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 105:2341-6. 2002

Detail Information

Publications326 found, 100 shown here

  1. ncbi Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
    James Shepherd
    University Department of Pathological Biochemistry, University of Glasgow, Royal Infirmary, Scotland, Glasgow, UK
    Lancet 360:1623-30. 2002
    ..Our aim was to test the benefits of pravastatin treatment in an elderly cohort of men and women with, or at high risk of developing, cardiovascular disease and ..
  2. ncbi Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study
    D J Freeman
    Department of Biological Sciences, University of Durham, Durham, UK
    Circulation 103:357-62. 2001
    ..cell count, systolic blood pressure, total and HDL cholesterol, glucose, and randomized treatment assignment to pravastatin were significant predictors...
  3. ncbi Long-term follow-up of the West of Scotland Coronary Prevention Study
    Ian Ford
    Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom
    N Engl J Med 357:1477-86. 2007
    The West of Scotland Coronary Prevention Study was a randomized clinical trial comparing pravastatin with placebo in men with hypercholesterolemia who did not have a history of myocardial infarction, with an average follow-up of ..
  4. ncbi Differential metabolic effects of distinct statins
    Kwang Kon Koh
    Vascular Medicine and Atherosclerosis Unit, Cardiology, Gachon University, Gil Medical Center, 1198 Kuwol dong, Namdong gu, Incheon 405 760, Republic of Korea
    Atherosclerosis 215:1-8. 2011
    ..b>Pravastatin increases expression of adiponectin mRNA, enhances adiponectin secretion, increases plasma levels of ..
  5. ncbi Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial
    Haruo Nakamura
    Mitsukoshi Health and Welfare Foundation, Tokyo, Japan
    Lancet 368:1155-63. 2006
    ..Our aim was to assess whether evidence for treatment with statins derived from western populations can be extrapolated to the Japanese population...
  6. ncbi Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial
    Ming Yuan Tseng
    Department of Neurosurgery, Addenbrooke s Hospital, University of Cambridge, Cambridge CB2 2QQ, United Kingdom
    Stroke 36:1627-32. 2005
    ..A phase II randomized controlled trial was conducted to examine the hypothesis that acute pravastatin treatment could improve cerebrovascular autoregulation and reduce vasospasm-related complications after ..
  7. pmc Genome-wide association of lipid-lowering response to statins in combined study populations
    Mathew J Barber
    Department of Human Genetics, University of Chicago, Chicago, Illinois, United States of America
    PLoS ONE 5:e9763. 2010
    ..To identify single nucleotide polymorphisms (SNPs) contributing to this variation, we performed a combined analysis of genome-wide association (GWA) results from three trials of statin efficacy...
  8. ncbi Pravastatin limits radiation-induced vascular dysfunction in the skin
    Valerie Holler
    Institute for Radiological Protection and Nuclear Safety IRSN, DRPH, SRBE, Laboratory of Radiopathology, Fontenay aux Roses, France
    J Invest Dermatol 129:1280-91. 2009
    ..endothelial nitric oxide synthase (eNOS)(-/-) mice were subjected to dorsal skin irradiation and treated with pravastatin for 28 days...
  9. pmc Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels
    N P Tatonetti
    Biomedical Informatics Training Program, Stanford University, Stanford, California, USA
    Clin Pharmacol Ther 90:133-42. 2011
    The lipid-lowering agent pravastatin and the antidepressant paroxetine are among the most widely prescribed drugs in the world. Unexpected interactions between them could have important public health implications...
  10. ncbi Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project
    Marc A Pfeffer
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 105:2341-6. 2002
    ..Therapeutic decisions regarding pharmacological therapy should be based on safety and tolerability as well as efficacy data. Clinical trials designed to assess efficacy are often insufficiently powered to generate reliable safety data...
  11. pmc Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients
    Kwang Kon Koh
    Cardiology, Gil Medical Center, Gachon University, Incheon, Republic of Korea
    Atherosclerosis 204:483-90. 2009
    ..Therefore, we hypothesized that simvastatin and pravastatin may have differential metabolic effects in hypercholesterolemic patients.
  12. ncbi Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE)
    Prakash Deedwania
    UCSF School of Medicine, San Francisco, Calif, USA
    Circulation 115:700-7. 2007
    ..However, no studies to date have assessed intensive versus moderate statin therapy in older patients with stable coronary syndromes...
  13. ncbi Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans
    Takao Watanabe
    Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan
    J Pharmacol Exp Ther 328:652-62. 2009
    ..resistance-associated protein (MRP) 2, is the major elimination pathway of an HMG-CoA reductase inhibitor, pravastatin. The present study examined the effects of changes in the transporter activities on the systemic and liver ..
  14. ncbi Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria:Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT)
    Frank P Brouwers
    Department of Cardiology, Thoraxcenter, Universitair Medical Center Groningen, University of Groningen, The Netherlands
    Am Heart J 161:1171-8. 2011
    ..We obtained extended follow-up data to approximately 10 years to investigate the long-term effects of fosinopril 20 mg and pravastatin 40 mg on cardiovascular outcomes in subjects with UAE >15 mg per 24 hours.
  15. ncbi Effect of pravastatin on cardiovascular events in people with chronic kidney disease
    Marcello Tonelli
    Division of Nephrology, University of Alberta, 7 129 Clinical Science Building, 8440 112 St, Edmonton, Alberta T6G 2G3, Canada
    Circulation 110:1557-63. 2004
    ..The objective of this analysis was to determine whether pravastatin reduced the incidence of cardiovascular events in people with or at high risk for coronary disease and with ..
  16. ncbi Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level
    Yuji Ishibashi
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Metabolism 61:1067-72. 2012
    ..We examined here whether and how pravastatin could block the AGEs-RAGE-elicited tubular cell injury in vitro...
  17. ncbi Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin
    Jenni E Keskitalo
    Department of Clinical Pharmacology, Helsinki University Central Hospital, Finland
    Pharmacogenomics 10:1617-24. 2009
    This study aimed to investigate possible effects of the ABCG2 c.421C>A (p.Gln141Lys; rs2231142) genotype on fluvastatin, pravastatin and simvastatin pharmacokinetics.
  18. ncbi Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin
    Masaru Hirano
    Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo, 113 0033 Japan
    J Pharmacol Exp Ther 314:876-82. 2005
    b>Pravastatin is a well known 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor...
  19. pmc Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial
    S Kawata
    Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Osaka, 565 0871, Japan
    Br J Cancer 84:886-91. 2001
    ..To investigate whether pravastatin, a potent HMG-CoA reductase inhibitor, prolongs survival in patients with advanced HCC, this randomized ..
  20. ncbi Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency
    Susumu Yoshida
    The Cardiovascular Center, Kansai Medical University, 2 3 1 Shinmachi, Hirakata, Osaka 573 1191, Japan
    J Cardiol 54:192-8. 2009
    ..Contrast-induced nephropathy (CIN) is known to increase morbidity and mortality of cardiovascular disease. Recent studies have shown statins prevented CIN after contrast media exposure, but optimal statin type and dosage are still unknown...
  21. ncbi Effects of Xuezhikang and pravastatin on circulating endothelial progenitor cells in patients with essential hypertension
    Li Lu
    The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China
    Chin J Integr Med 15:266-71. 2009
    To investigate the impacts of Xuezhikang (XZK) or pravastatin combined with antihypertensive drugs on circulating endothelial progenitor cells (CEPCs) in essential hypertensive (EH) patients.
  22. ncbi Pravastatin and cognitive function in the elderly. Results of the PROSPER study
    Stella Trompet
    Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands
    J Neurol 257:85-90. 2010
    ..Here we present detailed cognitive outcomes from the randomized placebo-controlled PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)...
  23. ncbi Inhibition of cardiac remodeling by pravastatin is associated with amelioration of endoplasmic reticulum stress
    Hui Zhao
    Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan
    Hypertens Res 31:1977-87. 2008
    The aim of this study is to investigate whether pravastatin can inhibit cardiac remodeling and ameliorate endoplasmic reticulum (ER) stress caused by pressure overload or tumor necrosis factor alpha (TNFalpha)...
  24. ncbi Effect of pravastatin on the development of diabetes and adiponectin production
    Toshiyuki Takagi
    Department of Medicine and Pathophysiology, Graduate School of Frontier Bioscience, Graduate School of Medicine, Osaka University, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
    Atherosclerosis 196:114-21. 2008
    In the West of Scotland Coronary Prevention Study (WOSCOPS), treatment of hypercholesterolemic men with pravastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, reduced their likelihood to progress to ..
  25. ncbi Toxicity of statins on rat skeletal muscle mitochondria
    P Kaufmann
    Division of Clinical Pharmacology and Toxicology and Department of Research, University Hospital, 4031, Basel, Switzerland
    Cell Mol Life Sci 63:2415-25. 2006
    ..of four lipophilic stains (cerivastatin, fluvastatin, atorvastatin, simvastatin) and one hydrophilic statin (pravastatin)...
  26. pmc Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model
    Keiichi Kumasawa
    Department of Experimental Genome Research, Research Institute for Microbial Diseases, Osaka University, Suita 565 0871, Japan
    Proc Natl Acad Sci U S A 108:1451-5. 2011
    ..Intrauterine growth restriction was also observed. We further showed that pravastatin induced the VEGF-like angiogenic factor placental growth factor (PGF) and ameliorated the symptoms...
  27. ncbi Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization
    M Crisby
    Department of Neurology, Huddinge University Hospital, Stockholm, Sweden
    Circulation 103:926-33. 2001
    ..Therefore, we investigated the effect of 3 months of pravastatin treatment on composition of human carotid plaques removed during carotid endarterectomy...
  28. ncbi Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study
    Olga A Iakoubova
    Celera, Alameda, California 9450, USA
    J Am Coll Cardiol 51:449-55. 2008
    ..We explored whether the benefit of intensive versus moderate statin therapy would be greater in carriers of KIF6 719Arg than in noncarriers...
  29. ncbi Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators
    P M Ridker
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02115, USA
    Circulation 98:839-44. 1998
    We studied whether inflammation after myocardial infarction (MI) is a risk factor for recurrent coronary events and whether randomized treatment with pravastatin reduces that risk.
  30. ncbi Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment
    Jason Johnson
    Bristol Heart Institute, University of Bristol, Bristol, United Kingdom
    Circulation 111:1422-30. 2005
    ..the early time course of plaque development and destabilization in the brachiocephalic artery of the apolipoprotein E-knockout mouse, the effects of pravastatin thereon, and the effects of pravastatin on established unstable plaques.
  31. ncbi Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
    R John Simes
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Australia
    Circulation 105:1162-9. 2002
    The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) trial showed that pravastatin significantly reduced mortality and coronary heart disease (CHD) events in 9014 patients with known CHD and total cholesterol 4.0 to 7...
  32. ncbi Using pravastatin to improve the vascular reactivity in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia
    Maged M Costantine
    Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas 77555 0587, USA
    Obstet Gynecol 116:114-20. 2010
    To estimate the effects of pravastatin on the altered vascular function in a mouse model of preeclampsia induced by overexpression of soluble fms-like tyrosine kinase-1 (sFlt-1).
  33. ncbi Effects of acute pravastatin treatment on intensity of rescue therapy, length of inpatient stay, and 6-month outcome in patients after aneurysmal subarachnoid hemorrhage
    Ming Yuan Tseng
    Department of Neurosurgery, Addenbrooke s Hospital, University of Cambridge, Cambridge, UK
    Stroke 38:1545-50. 2007
    We have previously demonstrated that acute pravastatin therapy after aneurysmal subarachnoid hemorrhage ameliorates vasospasm-related delayed ischemic deficits...
  34. ncbi Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone
    Jiawei Chen
    Division of Cardiovascular Medicine, Univ of Arkansas for Medical Sciences, 4301 West Markham St, Slot 532, Little Rock, AR 72205 7199, USA
    Am J Physiol Heart Circ Physiol 291:H1738-45. 2006
    ..We examined the potential antifibrotic effect of the combination of a statin (pravastatin) and a PPAR-gamma ligand (pioglitazone) in ANG II-treated mouse cardiac fibroblasts...
  35. ncbi Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia
    Antonio F Saad
    1Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, USA
    Reprod Sci 21:138-45. 2014
    In order to determine the effects of pravastatin (Pra) on angiogenic and placental hypoxic imbalance in a model of preeclampsia induced by overexpression of soluble fms-like tyrosine kinase 1 (sFlt-1), we randomly allocated pregnant CD1 ..
  36. ncbi Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study
    Dianna Magliano
    Department of Epidemiology and Preventive Medicine, Monash University, Central and Eastern Clinical School, Alfred Hospital, Melbourne, Victoria
    Aust N Z J Public Health 27:649-53. 2003
    ..To assess the accuracy of the Australian National Death Index (NDI) in identifying deaths and recording cardiovascular and cancer causes of death...
  37. ncbi Association of leukocyte subtype counts with coronary atherosclerotic regression following pravastatin treatment
    Shigemasa Tani
    Department of Cardiology, Nihon University, Surugadai Hospital, Tokyo, Japan
    Am J Cardiol 104:464-9. 2009
    ..A 6-month prospective study was conducted in 84 patients treated with pravastatin. Plaque volume, as assessed by volumetric analysis using intravascular ultrasound, decreased significantly by ..
  38. ncbi High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs
    Dieter Lutjohann
    Department of Clinical Pharmacology, University of Bonn, Sigmund Freud Str 25, 53105 Bonn, Germany
    Steroids 69:431-8. 2004
    ..present work, we tested the possibility that high doses of lipophilic and hydrophilic statins, simvastatin and pravastatin, respectively, or a diet high in cholesterol could affect cholesterol homeostasis in the brain of guinea pigs...
  39. ncbi Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis
    Ching Feng Cheng
    Graduate Institute of Pharmacology and Toxicology and College of Medicine, Tzu Chi University, 701, Chung Yang Road, Section 3, Hualien City, Hualien 970, Taiwan
    Apoptosis 13:883-94. 2008
    ..toxicity induced by carboplatin, a second generation platinum-containing anti-cancer drug, and to test whether pravastatin can reduce this cardio-toxicity...
  40. ncbi Comparison of effects of serum n-3 to n-6 polyunsaturated fatty acid ratios on coronary atherosclerosis in patients treated with pitavastatin or pravastatin undergoing percutaneous coronary intervention
    Tsuyoshi Nozue
    Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Yokohama, Japan
    Am J Cardiol 111:1570-5. 2013
    ..the effects of n-3 to n-6 PUFA ratios on coronary atherosclerosis in patients treated with pitavastatin and pravastatin. Coronary atherosclerosis in nonculprit lesions in the percutaneous coronary intervention vessel was evaluated ..
  41. ncbi Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance
    Carl Kyrklund
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 73:538-44. 2003
    ..b>Pravastatin pharmacokinetics differs from those of these 3 statins, which are extensively metabolized...
  42. pmc Reduced glomerular filtration rate and its association with clinical outcome in older patients at risk of vascular events: secondary analysis
    Ian Ford
    Robertson Centre for Biostatistics, University of Glasgow, Glasgow, Scotland
    PLoS Med 6:e16. 2009
    ..We aimed to determine the predictive value of the GFR for mortality and morbidity using data from the 5,804 participants randomized in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
  43. ncbi Pravastatin versus simvastatin for prevention of contrast-induced nephropathy
    Monica A Muñoz
    Department of Pharmacy, University Health System, San Antonio, TX, USA
    J Cardiovasc Pharmacol Ther 16:376-9. 2011
    ..retrospective, single-center trial was to compare the incidence of CIN in patients receiving simvastatin or pravastatin therapy undergoing percutaneous coronary intervention (PCI)...
  44. ncbi Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients
    Kwang Kon Koh
    Gil Medical Center, Gachon University, Incheon, Republic of Korea
    Int J Cardiol 166:509-15. 2013
    Rosuvastatin and pravastatin have differential hydrophilicity and potency to inhibit hydroxymethylglutaryl-CoA reductase that may be relevant to changes in adiponectin levels, insulin resistance, and the rate of new onset diabetes in ..
  45. ncbi The disposition of pravastatin in a rat model of streptozotocin-induced diabetes and organic anion transporting polypeptide 2 and multidrug resistance-associated protein 2 expression in the liver
    Yoshitaka Hasegawa
    Laboratory of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Japan
    Biol Pharm Bull 33:153-6. 2010
    ..3-Hydroxy-3-methylglutaryl enzyme A (HMG-CoA) reductase inhibitors (statins), like pravastatin, are frequently administered to diabetic patients for this purpose...
  46. ncbi KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly
    Hironobu Akao
    Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University and Tufts University School of Medicine, Boston, MA, USA
    Atherosclerosis 220:456-62. 2012
    ..LPA (rs3798220), TAS2R50 (rs1376251) and VAMP8 (rs1010) in 5,411 participants in PROSPER (PROspective Study of Pravastatin in the Elderly at Risk) (mean age 75...
  47. ncbi The impact of pravastatin pre-treatment on periprocedural microcirculatory damage in patients undergoing percutaneous coronary intervention
    Kenichi Fujii
    Cardiovascular Division, Hyogo College of Medicine, Nishinomiya, Japan
    JACC Cardiovasc Interv 4:513-20. 2011
    This study evaluated the effect of pravastatin pre-treatment on post-procedural index of microcirculatory resistance (IMR) values that are introduced for assessing the status of the microcirculation independently of the epicardial area.
  48. ncbi Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia
    Liliana Grigore
    Center for the Study of Atherosclerosis SISA Lombardia, Bassini Hospital, Via Gorki 50, 20092 Cinisello Balsamo, Milan, Italy
    Eur J Clin Pharmacol 69:341-6. 2013
    ..The aim of this study was to evaluate whether the effect of pravastatin on endothelial function is mediated by pleiotropic effects...
  49. ncbi Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia
    Karin A Fox
    Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston, TX, USA
    Am J Obstet Gynecol 205:366.e1-5. 2011
    We sought to investigate the mechanisms of action by which pravastatin improves vascular reactivity in a mouse model of preeclampsia induced by overexpression of soluble Fms-like tyrosine kinase-1 (sFlt)-1.
  50. ncbi Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors
    B Wolozin
    Department of Pharmacology, Loyola University Medical Center, Bldg 102, Room 3634, 2160 S First Ave, Maywood, IL 60153
    Arch Neurol 57:1439-43. 2000
    ..Increasing evidence suggests that cholesterol plays a role in the pathophysiology of Alzheimer disease (AD). For instance, an elevated serum cholesterol level has been shown to be a risk factor for AD...
  51. ncbi Pravastatin reduces Marfan aortic dilation
    Darren McLoughlin
    Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland
    Circulation 124:S168-73. 2011
    ..This study examined the efficacy and mechanism of statins in attenuating aortic root dilation in Marfan syndrome and compared effects to the other main proposed preventative agent, losartan...
  52. ncbi Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study
    Christie M Ballantyne
    Baylor College of Medicine, and Methodist DeBakey Heart and Vascular Center, Houston, TX 77030, USA
    Am Heart J 163:515-21, 521.e1-3. 2012
    ..This study analyzed the effect of dalcetrapib on lipoprotein profile, CETP activity, and cellular cholesterol efflux when co-administered with pravastatin in patients with low or average HDL-C.
  53. ncbi Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
    J K Williams
    Department of Comparative Medicine, Wake Forest University, Winston Salem, North Carolina 27157 1040, USA
    J Am Coll Cardiol 31:684-91. 1998
    This study examined the direct effects of pravastatin on the artery wall of atherosclerotic monkeys after dietary lipid lowering.
  54. ncbi Pravastatin therapy and the risk of stroke
    H D White
    Cardiology Department, Green Lane Hospital, Auckland, New Zealand
    N Engl J Med 343:317-26. 2000
    ..Recent reviews of trials of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors have suggested that these agents may reduce the risk of stroke...
  55. ncbi Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events
    M A Pfeffer
    Department of Medicine, Brigham and Women s Hospital and Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 33:125-30. 1999
    We sought to assess the influence of baseline lipid levels on coronary event rates and the effectiveness of pravastatin therapy in the Cholesterol And Recurrent Events (CARE) study.
  56. ncbi Statins and prostate cancer diagnosis and grade in a veterans population
    Wildon R Farwell
    Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston, MA 02130, USA
    J Natl Cancer Inst 103:885-92. 2011
    ..Although prostate cancer is commonly diagnosed, few risk factors for high-grade prostate cancer are known and few prevention strategies exist. Statins have been proposed as a possible treatment to prevent prostate cancer...
  57. ncbi Relaxant effects of pravastatin, atorvastatin and cerivastatin on isolated rat aortic rings
    B Sönmez Uydeş-Doğan
    Istanbul University Faculty of Pharmacy, Department of Pharmacology, 34116, Beyazit, Istanbul, Turkey
    Life Sci 76:1771-86. 2005
    ..In the present study, we investigated the acute vascular effects of pravastatin, atorvastatin and cerivastatin on rat isolated aortic rings...
  58. ncbi Graft-protective effects of the HMG-CoA reductase inhibitor pravastatin after lung transplantation--a propensity score analysis with 23 years of follow-up
    Yijiang Li
    Hannover Thoracic Transplant Program, Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
    Transplantation 92:486-92. 2011
    To determine whether the hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin has a graft-protective effect, we retrospectively analyzed 502 patients who had undergone lung transplantation in Hannover.
  59. ncbi Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure
    Sahoko Ichihara
    Department of Cardiovascular Genome Science, Nagoya University School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya 466 8550, Japan
    Cardiovasc Res 69:726-35. 2006
    ..We have now investigated the role of MMPs and their tissue inhibitors (TIMPs) in the transition from compensated left ventricular (LV) hypertrophy to heart failure as well as the effects of pravastatin on this transition in a rat model.
  60. pmc Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites
    David G Menter
    Department of Cancer Biology, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    PLoS ONE 6:e28813. 2011
    ..b>Pravastatin is a hydrophilic statin that is selectively taken up by a sodium-independent organic anion transporter protein-..
  61. ncbi Oral pravastatin prolongs survival time of scrapie-infected mice
    Vito Vetrugno
    Department of Cell Biology and Neurosciences, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy
    J Gen Virol 90:1775-80. 2009
    ..They are either lipophilic (e.g. simvastatin) or hydrophilic [e.g. pravastatin (PRV)] compounds, considered mainly for long-term treatment of hypercholesterolaemic individuals...
  62. ncbi Pleiotropic phenotypes caused by an opal nonsense mutation in an essential gene encoding HMG-CoA reductase in fission yeast
    Yue Fang
    Division of Molecular Pharmacology and Pharmacogenomics, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, 7 5 1 Kusunoki cho, Chuo Ku, Kobe 650 0017, Japan
    Genes Cells 14:759-71. 2009
    ..The hmg1-1 mutant showed hypersensitivity to pravastatin, an HMGR inhibitor, suggesting a defective HMGR activity...
  63. ncbi Pravastatin down-regulates inflammatory mediators in human monocytes in vitro
    O Grip
    Department of Medicine, Division of Gastroenterology and Hepatology, Lund University, University Hospital MAS, S 20502, Malmo, Sweden
    Eur J Pharmacol 410:83-92. 2000
    There is experimental evidence that pravastatin, which is designed to inhibit the rate-limiting enzyme of cholesterol synthesis, can affect cell metabolism and proliferation...
  64. ncbi Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study
    Shinichi Sato
    Osaka Medical Center for Health Science and Promotion, Nakamichi, Osaka, Japan
    J Epidemiol 16:201-6. 2006
    ..The aim of this study was to investigate the association between statin-therapy and the incidence of cancer in coronary heart disease patients...
  65. ncbi Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein
    Keita Sano
    Department of Internal Medicine II, Faculty of Medicine, University of Yamanashi, Chuo, Japan
    Circ J 74:1644-50. 2010
    ..This study examined which of 2 common lipid-lowering drugs (fibrates and statins) is more effective in patients with remnant lipoproteinemia and if lowering remnant lipoprotein levels can reduce CV risk...
  66. ncbi Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators
    R A Stewart
    Cardiovascular Research Unit, Green Lane Hospital, Private Bag 92189, Auckland 1030, New Zealand
    Arch Intern Med 160:3144-52. 2000
    ..The aim of this study was to identify or exclude any small or infrequent adverse effect of long-term reduction of serum cholesterol with pravastatin sodium on psychological well-being.
  67. ncbi Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension
    Tsung Ming Lee
    Cardiology Section, Department of Medicine, Taipei Medical University and Chi Mei Medical Center, Tainan, Taiwan
    Clin Sci (Lond) 116:497-505. 2009
    ..In the present study, we assessed whether pravastatin administration was effective in improving PH and exercise capacity in COPD patients with PH, and whether the ..
  68. ncbi Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR
    Sean R Wilson
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 161:1147-55.e1. 2011
    ..Recent data have suggested a possible discordant adverse risk relationship in acute coronary syndrome (ACS). Therefore, we investigated the association between adiponectin and cardiovascular events in patients with ACS...
  69. ncbi Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study
    Demosthenes Makris
    Department of Critical Care Medicine, University Hospital of Larissa, Larissa, Greece
    Crit Care Med 39:2440-6. 2011
    To investigate whether the use of pravastatin reduces the frequency of ventilator-associated pneumonia and whether it is related to favorable outcomes in critical care patients.
  70. ncbi Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study
    Loukianos S Rallidis
    Atherosclerosis 174:193-6. 2004
  71. ncbi Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance
    Steven C Halbert
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Am J Cardiol 105:198-204. 2010
    ..The present trial evaluated the tolerability of red yeast rice versus pravastatin in patients unable to tolerate other statins because of myalgia...
  72. ncbi Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors
    Terry A Jacobson
    Office of Health Promotion and Disease Prevention, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia 30303, USA
    Am J Cardiol 94:1140-6. 2004
    ..Studies compared the multiple-dose pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with 4 inhibitors of cytochrome P450-3A4 isoenzymes in ..
  73. pmc Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial
    Nirupa R Matthan
    Cardiovascular Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA
    J Lipid Res 51:202-9. 2010
    ..Nonetheless, CHD events still occur in some treated patients. To address differences in outcome during pravastatin therapy (40 mg/day), plasma markers of cholesterol synthesis (desmosterol, lathosterol) and fractional ..
  74. ncbi The 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor pravastatin enhances neurite outgrowth in hippocampal neurons
    Amy M Pooler
    Department of Brain and Cognitive Sciences, Harvard University Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
    J Neurochem 97:716-23. 2006
    ..To determine whether statins affect neuronal development, we treated cultured rat hippocampal neurons with pravastatin. After 4-48 h of treatment, pravastatin significantly increased the number of neurites produced by each cell ..
  75. ncbi Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II-induced hypertensive mice
    Zhujie Xu
    Department of Cardiovascular Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
    J Cardiovasc Pharmacol 51:62-70. 2008
    ..However, the exact mechanisms of statins possibly explaining the decreased cardiovascular morbidity and mortality in patients with DHF have not been elucidated...
  76. ncbi Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project
    F M Sacks
    Brigham and Women s Hospital, Harvard Medical School Boston, MA 02115, USA
    Circulation 102:1893-900. 2000
    ..Previous trials have had insufficient numbers of coronary events to address definitively the effect of lipid-modifying therapy on coronary heart disease in subgroups of patients with varying baseline characteristics...
  77. ncbi The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study
    Kenji Sakamoto
    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
    Clin Ther 28:1012-21. 2006
    b>Pravastatin has been reported to reduce cardiovascular events and mortality in patients with coronary artery disease (CAD). Hypoadiponectinemia is a known risk factor for CAD.
  78. pmc Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial
    David A Morrow
    Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 155:49-55. 2008
    ..Elevated concentrations of MRP-8/14 are associated with a higher risk for future cardiovascular events in apparently healthy individuals but have not been assessed with respect to prognosis in patients with acute coronary syndrome...
  79. ncbi Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis I
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 54:2290-5. 2009
    ....
  80. ncbi Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting
    R Pena
    Unidad de Arteriosclerosis, Hospital Carlos III, Madrid, Spain
    J Intern Med 251:518-25. 2002
    ..objective of the present study was to evaluate the effect of the apoE genotype on the lipoprotein response to pravastatin treatment in an outpatient population followed-up in several different clinics across Spain...
  81. ncbi Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease
    I R Reid
    Department of Medicine, University of Auckland, New Zealand
    Lancet 357:509-12. 2001
    ..To assess whether statins have clinically significant effects on bone, we studied the frequency of fractures in a large randomised controlled trial of these agents...
  82. ncbi Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction)
    Michelle O'Donoghue
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Circulation 113:1745-52. 2006
    ..The prognostic value of Lp-PLA2 in patients with acute coronary syndromes (ACS) has not been established...
  83. ncbi Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats
    Kari T Kivistö
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Drug Metab Dispos 33:1593-6. 2005
    ..role of the efflux transporter Mrp2 (Abcc2) in the pharmacokinetics of orally and intravenously administered pravastatin in rats. Eight Mrp2-deficient TR- rats and eight wild-type rats were given an oral dose of 20 mg/kg pravastatin...
  84. ncbi Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound
    Shigemasa Tani
    Department of Cardiology, Nihon University Surugadai Hospital, Tokyo, Japan
    Am J Cardiol 96:1089-94. 2005
    ..This study investigated the effects of pravastatin on the serum levels of MDA-LDL and coronary atherosclerosis...
  85. ncbi Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans
    Kari T Kivistö
    Department of Pharmacological Sciences, Medical School, University of Tampere, Tampere 33014, Finland
    Pharm Res 24:239-47. 2007
    The role of drug transporters in pravastatin disposition is underlined by the fact that pravastatin does not undergo significant cytochrome P-450 (CYP)-mediated biotransformation...
  86. ncbi Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria
    Folkert W Asselbergs
    Department of Clinical Pharmacology, University of Groningen, Groningen, The Netherlands
    Circulation 110:2809-16. 2004
    ..We assessed whether therapeutic intervention aimed at lowering urinary albumin excretion would reduce cardiovascular events in microalbuminuric subjects (15 to 300 mg/24 hours)...
  87. ncbi High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
    Mikko Niemi
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenetics 14:429-40. 2004
    ..protein 2 (MRP2, ABCC2) and multidrug resistance transporter (MDR1, ABCB1) and the pharmacokinetics of pravastatin. We studied 41 healthy Caucasian volunteers who had previously participated in pharmacokinetic studies with ..
  88. ncbi Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site
    G Weitz-Schmidt
    Novartis Pharma AG, Preclinical Research, Basel, Switzerland
    Nat Med 7:687-92. 2001
    ..Targeting of the statin-binding site of LFA-1 could be used to treat diseases such as psoriasis, rheumatoid arthritis, ischemia/reperfusion injury and transplant rejection...
  89. ncbi Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats
    Valerie Haydont
    UPRES EA 27 10 Radiosensibilité des tumeurs et tissus sains, Institut de Radioprotection et de Sûreté Nucléaire Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 13:5331-40. 2007
    ..Among these new targets, we identified the Rho/ROCK pathway and thought to investigate whether pravastatin treatment inhibits Rho pathway activation and elicits an antifibrotic action.
  90. ncbi Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin
    Pertti J Neuvonen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacokinet 47:463-74. 2008
    ..and interaction potentials of the possible OTC candidate statins simvastatin, lovastatin, fluvastatin and pravastatin are clearly different...
  91. ncbi Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators
    P M Ridker
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, The Children s Hospital Medical Center, Boston, MA, USA
    Circulation 100:230-5. 1999
    ..We evaluated whether long-term therapy with pravastatin, an agent that reduces cardiovascular risk, might alter levels of this inflammatory parameter.
  92. ncbi Pravastatin inhibits expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in Watanabe heritable hyperlipidemic rabbits: a new pleiotropic effect of statins
    Oliver Hofnagel
    Leibniz Institute for Arteriosclerosis Research, University Hospital of Muenster, Germany
    Arterioscler Thromb Vasc Biol 26:604-10. 2006
    ..Because statins are able to downregulate LOX-1 expression in vitro, we examined if pravastatin can be used to reduce LOX-1 expression and lipid core formation in lesions of Watanabe heritable hyperlipidemic ..
  93. ncbi Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events
    T Hatanaka
    Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, Japan
    Clin Pharmacokinet 39:397-412. 2000
    b>Pravastatin, one of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) widely used in the management of hypercholesterolaemia, has unique pharmacokinetic characteristics among the members of this class...
  94. ncbi Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients
    Marie Hélène Gannagé-Yared
    Division of Endocrinology, Hotel Dieu de France Hospital, Beirut, Lebanon
    Metabolism 54:947-51. 2005
    ..The effect of statins on insulin resistance is controversial and poorly studied in nondiabetic subjects. In addition, the effect of statins on leptin and adiponectin has never been studied...
  95. pmc Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events?
    Naveed Sattar
    Division of Cardiovascular and Medical Sciences, Faculty of Medicine, University of Glasgow, Glasgow, Scotland, UK
    PLoS Med 6:e1000099. 2009
    ..We tested whether interleukin (IL)-6, C-reactive protein (CRP), and fibrinogen more strongly associate with fatal compared to nonfatal myocardial infarction (MI) and stroke...
  96. pmc Hyperglycemia induces apoptosis of human pancreatic islet endothelial cells: effects of pravastatin on the Akt survival pathway
    Enrica Favaro
    Department of Internal Medicine, University of Torino, Torino, Italy
    Am J Pathol 173:442-50. 2008
    ..Apoptosis was accompanied by a reduced p-Akt/Akt ratio and inhibition of nephrin tyrosine phosphorylation. Pravastatin (1 mumol/L) decreased apoptosis induced by high glucose or oxidized LDL and increased Akt phosphorylation...
  97. ncbi Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells
    Mayumi Ishikawa
    Department of Internal Medicine Endocrinology and Metabolism Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan
    J Atheroscler Thromb 13:329-35. 2006
    ..the direct effects of statins on insulin secretion from pancreatic beta-cells, MIN6 cells were treated with pravastatin, simvastatin, or atorvastatin...
  98. ncbi Effects of pravastatin in murine collagen-induced arthritis
    Toshiaki Yamagata
    Department of Nephrology and Rheumatology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama, Osaka 589 8511, Japan
    Rheumatol Int 27:631-9. 2007
    ..DBA/1 mice were immunized with bovine type-II collagen and administered 100 mg/kg of pravastatin interperitoneally...
  99. ncbi A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters
    B Hsiang
    Bristol Myers Squibb Co, Pharmaceutical Research Institute, Princeton, New Jersey 08543 4000, USA
    J Biol Chem 274:37161-8. 1999
    ..sulfate, and thyroid hormone, as well as the hydroxymethylglutaryl-CoA reductase inhibitor, pravastatin. OATP2 is expressed exclusively in liver in contrast to all other known transporter subtypes that are found in ..
  100. ncbi Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)
    Peter H Jones
    Baylor College of Medicine, 6565 Fannin Avenue, A 601, Houston, TX 77030, USA
    Am J Cardiol 92:152-60. 2003
    ..parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose ranges for reduction of low-density lipoprotein (LDL) cholesterol...
  101. ncbi Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease
    P Sterzer
    Department of Neurology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Stroke 32:2817-20. 2001
    ..Using transcranial Doppler sonography (TCD), we examined acetazolamide reactivity as a marker of cerebral vasoreactivity in patients with subcortical small-vessel disease before and after pravastatin treatment.

Research Grants62

  1. Cholesterol induces oxidative stress and triggers iron and A? accumulation
    Othman Ghribi; Fiscal Year: 2012
    ..We will compare the effects of pravastatin (a hydrophilic statin that has a low propensity to cross the BBB) and simvastatin (a lipophilic statin that ..
  2. Effect of Statin Therapy on Disease Progression in Children with ADPKD
    Robert W Schrier; Fiscal Year: 2012
    ..This study is designed to determine if treatment with the medicines, pravastatin and lisinopril, can slow the progression of kidney and heart disease when initiated early in life in patients ..
  3. Phase II Trial of Lonafarnib, Pravastatin and Zoledronic Acid in Progeria
    MARK WILLIAM KIERAN; Fiscal Year: 2010
    ..This open label phase II efficacy trial will evaluate pravastatin, zoledronic acid and lonafarnib, and is based on our two previous clinical trials for HGPS...
  4. Improved actions of nitrates and statins with L-arginine
    Ruth Caldwell; Fiscal Year: 2003
    ..and congestive heart failure using nitroglycerin (GTN) or isosorbide mononitrate (ISMN) and 2) statin therapy [pravastatin (PRA) or simvastatin (SIM)] for unstable angina and stroke, by their combination with L-arginine (L-arginine)...
  5. TDM & Drug Interactions in HIVinfected Substance Abusers
    Gene Morse; Fiscal Year: 2007
    ..inhibitors (NNRTIs), and commonly prescribed medications including methadone, ethinyl estradiol, fluconazole, pravastatin, and fluoxetine in HIV-infected, substance abusers The proposed methodology employs a Therapeutic Drug ..
  6. The Role of Statin Lactones in Statin Toxicity
    Uwe Christians; Fiscal Year: 2006
    ..potential role of the lactones of statins administered as open acids (atorvastatin, cerivastatin, fluvastatin, pravastatin) in pharmacokinetic and pharmacodynamic drug interactions and toxicity...
  7. Maternal Fetal Medicine Network
    Ronald Wapner; Fiscal Year: 2013
    ..Within this application is a concept evaluating the potential of statins (pravastatin) to treat and/or prevent preeclampsia in very high risk pregnancies...
  8. Effects of Statins on AD beyond Cholesterol and Amyloid
    Ling Li; Fiscal Year: 2006
    ..This hypothesis will be tested by two Specific Aims: 1) to determine the efficacy of statins (simvastatin and pravastatin) and a non-statin cholesterol-lowering drug (ezetimibe) in modulating AD-type behavior and pathology in a mouse ..
  9. CLINICAL TRIALS CENTER FOR ALLHAT
    Barry Davis; Fiscal Year: 2000
    ..is lower in moderately hypercholesterolemic men women patients receiving the cholesterol- lowering drug pravastatin (HMG CoA reductase inhibitor), than in an open "usual care" control group...
  10. Improving AML Therapy outcome by Cholesterol Modulation
    Frederick Appelbaum; Fiscal Year: 2006
    ..Since pravastatin produces fewer adverse drug-drug interactions than other commonly-prescribed statins, we designed a Phase 1 ..
  11. Clinical importance of the drug interaction between statins and SYP3A inhibitors
    BRIAN STROM; Fiscal Year: 2009
    ..of myopathy and acute kidney injury following concomitant use of a non-3A4 substrate statin [fluvastatin, pravastatin, or rosuvastatin] and a CYP3A4 inhibitor...
  12. HEPATIC DRUG TRANSPORTERS IN DRUG DISPOSITION
    Dan Roden; Fiscal Year: 2006
    ..significant in vitro, will be tested in human subjects using the well-known OATP-C-specific substrate, pravastatin, and a newly identified substrate, rifampin, as in vivo probes for this transporter...
  13. ISLET-KIDNEY TRANSPLANTATION FOR TYPE I DIABETES
    Fouad Kandeel; Fiscal Year: 2006
    ..Treatment of recipients with pravastatin may also increase the islet mass through its ability to prevent non-specific inflammatory damage to islets, as ..
  14. CORONARY ANGIOGRAPHIC TRIAL OF ESTROGEN THERAPY
    HOWARD HODIS; Fiscal Year: 2001
    ..All arms will receive lipid-lowering therapy, low-fat low cholesterol diet and pravastatin in sufficient dosage to reduce LDL-cholesterol levels below 130 mg/dL...
  15. Novel Therapies in Idiopathic Pulmonary Fibrosis
    Kevin Brown; Fiscal Year: 2009
    ..clinical research network, the efficacy of one multi-drug (N-acetyl cysteine [NAC], clarithromycin, and pravastatin) and a novel therapy (prostaglandin 12 [PG12], prostacyclin or its analogues) in the treatment of IPF...
  16. Pharmacogenomics and Risk of Cardiovascular Disease
    Ronald Krauss; Fiscal Year: 2009
    ..Initial analyses in 1,000 Caucasian subjects from trials of simvastatin or pravastatin will be based on a panel of 250,000 genome-wide SNPs (Aim 1)...
  17. RCT OF PREVENTION OF ACCELERATED ATHEROSCLEROSIS IN SLE
    MATTHEW LIANG; Fiscal Year: 2000
    ..randomized controlled trial of an aggressive atherosclerosis vascular disease modifying strategy is aimed at primary prevention using B complex vitamins, Pravastatin, an a novel telephone risk factor management system in women with SLE.
  18. Dietary Macronutrients and Weight Loss
    Frank Sacks; Fiscal Year: 2008
    ..The results will be straightforwardly applicable to public health and clinical guidelines for obesity, and will increase our understanding of the biology of obesity and weight loss. ..
  19. VLDL and LDL Particle Types as CHD Risk Factors
    Frank Sacks; Fiscal Year: 2006
    ..abstract_text> ..
  20. Apo A2, C1 and C2 and Diet in human apoB Metabolism
    Frank Sacks; Fiscal Year: 2005
    ..abstract_text> ..
  21. KINETICS OF HUMAN POSTPRANDIAL LIPOPROTEIN METABOLISM
    Frank Sacks; Fiscal Year: 2001
    ..These studies will increase our understanding of the metabolic pathways that are activated or suppressed postprandially, and could lead to treatments for reducing the development of atherosclerosis. ..
  22. Determining Therapeutic Efficacy of AGE in AD
    Neelima Chauhan; Fiscal Year: 2005
    ..If successful, this project will validate the use of safe, naturally well-tolerated, cost-effective and alternative herbal pharmacotherapy for treating AD. ..
  23. STATINS AND NON-CARDIAC ENDPOINTS
    Beatrice Golomb; Fiscal Year: 2003
    ..that simvastatin (lipophilic) will exert more potent effects on cognition (and perhaps aggression) than pravastatin (hydrophilic); that serotonin (5HT) changes will related to changes in aggressive responding and perhaps ..
  24. THROMBOTIC, INFLAMMATORY & GENE MARKERS OF CVD IN WOMEN
    Paul Ridker; Fiscal Year: 2002
    ....
  25. MAC 1/LFA 1/P150 95 AND PMN LEUKOCYTE FUNCTION
    Christie Ballantyne; Fiscal Year: 2002
    ..3. Characterize the contribution of each CD11 integrin on the host response to common bacterial and fungal pathogens in vitro and in vivo. ..
  26. PROTEASE INHIBITOR-INDUCED HYPERLIPIDEMIA IN AIDS
    Virgil Brown; Fiscal Year: 2004
    ..These are specific agents that are effective in reducing triglyceride as well as improving insulin resistance. ..
  27. SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSIS
    Paul Ridker; Fiscal Year: 2002
    ....
  28. Obesity, Inflammation and Thrombosis: LOOK AHEAD
    Christie M Ballantyne; Fiscal Year: 2010
    ....
  29. Reduction of Amyloid Burden by Antisense APP
    Neelima Chauhan; Fiscal Year: 2005
    ..Significance: Targeting the translation of amyloidogenic APP by antisense synthetic oligodeoxynucleotides may prove to be an effective and safe form of gene therapy for treating familial AD and other genetic diseases. ..
  30. Coenzyme Q10 in Aging: A Planning Grant
    Beatrice Golomb; Fiscal Year: 2005
    ..Thus there is strong conceptual as well as clinical rationale for assessing whether Q10 provides QOL & functional benefits in aging and whether it protects against untoward events associated with age. ..
  31. Minocycline to Improve Neurologic Outcome (MINO Clinical Trial)
    David Hess; Fiscal Year: 2009
    ..Since it is a safe drug and may also have activity against intracerebral hemorrhage, minocycline has excellent potential to become a "field drug", administered by ambulance crews and in rural hospitals. ..
  32. Pathophysiology and Characterisation of NAFLD
    Michael Charlton; Fiscal Year: 2009
    ..We believe that these experiments will generate mechanistic insight into the cause and effects of increased oxidative stress in patients with histologically progressive NAFLD. ..
  33. DIETARY COMPOSITION, OBESITY, AND CARDIOVASCULAR RISK
    ERNST SCHAEFER; Fiscal Year: 2003
    ..abstract_text> ..
  34. The Effect of Statins on Skeletal Muscle Function
    PAUL DAVIS THOMPSON; Fiscal Year: 2010
    ....
  35. Diet-Induced Insulin Resistance and Myocardial Ischemia in Pigs
    Gregory Schwartz; Fiscal Year: 2008
    ..Therefore, an additional goal is to determine whether chronic treatment with a PPAR alpha or gamma agonist modifies myocardial metabolic and contractile dysfunction after I/R in insulin resistant pigs. ..
  36. DIETS FOR DYSLIPIDEMIA IN THE METABOLIC SYNDROME
    Robert Knopp; Fiscal Year: 2009
    ..This study will be the first to demonstrate dietary benefit for dyslipidemia, inflammation and vascular stress in MetS at stable weight. ..
  37. QUANTITATIVE IMAGING OF ZINC METABOLISM IN THE BRAIN
    Richard Thompson; Fiscal Year: 2003
    ..abstract_text> ..
  38. HDL metabolism: Influence of extracellular lipases
    Daniel Rader; Fiscal Year: 2009
    ....
  39. Fluorescence Zinc BioSensing and Imaging Technology
    RICHARD BLAIR THOMPSON; Fiscal Year: 2010
    ..This novel technology will provide the basis for new diagnostics and treatments. ..
  40. Salsalate: A Diabetes Treatment for Carbonyl, Oxidative & Nitrosative Stress
    JOSHUA ISRAEL BARZILAY; Fiscal Year: 2010
    ..If effective, this treatment could reduce the risk of heart attacks and strokes that frequently occur in people with diabetes. ..
  41. A Metabolomic Approach to Discovering Biomarkers for ADPKD
    Robert H Weiss; Fiscal Year: 2010
    ..In addition, work from this proposal will lead to new knowledge about the pathology of the disease and to selection of patients who will most benefit from any new drug. ..
  42. Identification of biomarkers of fatty acid intake
    Hannia Campos; Fiscal Year: 2002
    ..abstract_text> ..
  43. Effect of Urban Form on Exercise and BMI in Black Women
    Patricia Coogan; Fiscal Year: 2009
    ..The proposed study has the potential to provide such evidence and to impact policy in the domains of both transportation/urban planning and public health. ..
  44. BIOLOGY OF PROTEOLYTIC DERIVATIVES OF LP(A)
    ANGELO SCANU; Fiscal Year: 2009
    ..The results of the proposed studies should shed light on whether ox-PL adducts play a role in the cardiovascular pathogenicity of Lp(a). ..
  45. Validity of Diabetes Self-Reports in the Women's Health Initiative
    Karen Margolis; Fiscal Year: 2008
    ..The results of the study will help determine whether self-reported diabetes can be used for other analyses of the WHI data, and for post- menopausal women in other studies. [unreadable] [unreadable] [unreadable]..
  46. Regulation of eNOS by the cell division cycle homolog, cdc37
    Michael Harris; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  47. Risk of Type 1 and Type 2 Diabetes among Young Finns
    Jaakko Tuomilehto; Fiscal Year: 2005
    ..The detailed epidemiological data obtained in this study will also lay a foundation for further research of etiological factors, genetic and environmental, predisposing to DMI and DM2 in this age group. ..
  48. Atherothrombosis
    Peter Libby; Fiscal Year: 2005
    ..This effort will hasten the translation of research discoveries to promote health of the heart and blood vessels at home and abroad. ..
  49. CASE CONTROL STUDY OF STATIN USE AND LARGE BOWEL CANCER
    Patricia Coogan; Fiscal Year: 2004
    ..S. men and women are high, an inverse association would be of considerable public health importance. Moreover, it would shed light on a mechanism of colon carcinogenesis. ..
  50. Inflammation and Aortic Aneurysm Pathophysiology
    Galina Sukhova; Fiscal Year: 2006
    ....
  51. Inflammatory Mechanisms of Atherosclerosis
    Peter Libby; Fiscal Year: 2006
    ..5. We will explore a putative functional role of a novel prostaglandin E2 receptor EP4 interacting protein (EPRAP) in endogenous anti-inflammatory pathways. ..
  52. Oxidized Phospholipids and Angiogenesis
    Karol Watson; Fiscal Year: 2004
    ..Information derived from these experiments will contribute to understanding the role of lipid oxidation products in angiogenesis, and potentially explain the co- localization of atherosclerosis and angiogenesis in vivo. ..
  53. ACTION - A CHF Trial Investigating Outcomes of Exercise
    Gregg Fonarow; Fiscal Year: 2006
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
  54. Pharmacogenetics of the Statin Response
    ERNST SCHAEFER; Fiscal Year: 2006
    ..studies), we propose to study 2804 male and 3000 female participants in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER), who were selected for age 70-82 years, having vascular disease coronary, ..
  55. Physiogenomic Arrays for Clinical Neuropsychiatry
    GUALBERTO RUANO; Fiscal Year: 2006
    ..The program will develop NeuroPsych Gene Array products as a new tool for systems understanding of neuropsychiatric and neurodegenerative diseases leading to early diagnosis and personalized therapy. [unreadable] [unreadable]..
  56. Mentored Career Development in Patient Oriented Research
    Daniel Rader; Fiscal Year: 2006
    ..abstract_text> ..
  57. Spirituality and Will to Live in Patients with HIV/AIDS
    Joel Tsevat; Fiscal Year: 2004
    ..We anticipate that such information will be of great benefit to patients with HIV/AIDS in their quest to make the best of a potentially devastating illness. ..
  58. Mentorship and Research in Spirituality and Health
    Joel Tsevat; Fiscal Year: 2007
    ..abstract_text> ..
  59. GENETICS OF ADIPOSITY AND GLUCOSE HOMEOSTASIS
    Carlos Lorenzo; Fiscal Year: 2008
    ....
  60. GENE-DIET INTERACTIONS AND HEART DISEASE
    HANNAI CAMPOS; Fiscal Year: 2003
    ..This study will provide the most complete data set to study numerous hypotheses relating genes, diet, and CHD, and could lead to specific targeted interventions for reducing the development of CHD. ..
  61. Univ. of Cincinnati Clinical Curriculum Award
    Joel Tsevat; Fiscal Year: 2008
    ..Coupled with the very strong financial support and enthusiasm of the leadership of the University, we anticipate that the CRCA will have a huge impact on clinical research training in Cincinnati. ..
  62. Lipid Testing /Treatment in Older MI Patients
    JoAnne Foody; Fiscal Year: 2005
    ..This work will ultimately improve care for the elderly patient with cardiovascular disease. ..